nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.10.2004 | Review

Replicative senescence of CD8 T cells: potential effects on cancer immune surveillance and immunotherapy

verfasst von: Rita B. Effros

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 10/2004

Einloggen, um Zugang zu erhalten

Abstract

The process of replicative senescence, which stringently limits the proliferative potential of normal T cells, constitutes a potential problem for cancer immunotherapy. The ability of CD8 T cells to recognize and destroy tumor cells has been well-established, but the requirement for massive, prolonged proliferative T-cell expansion and maintenance of functional integrity poses a significant obstacle to the success of cancer immunotherapy. Cancer immune surveillance may also be compromised by the long-term exposure of T cells to tumor antigens, particularly those of latent viruses, which could drive certain T cells to replicative senescence. This review summarizes the major characteristics of T-cell replicative senescence and raises the possibility that this process has the potential to affect both cancer development and treatment. Experimental strategies aimed at preventing T-cell replicative senescence are discussed in the context of cancer immunotherapy and vaccines.

Alexandroff AB, McIntyre CA, Porter JC, Zeuthen J, Vile RG, Taub DD (1998) Sticky and smelly issues: lessons on tumour cell and leucocyte trafficking, gene and immunotherapy of cancer. Br J Cancer 77:1806PubMed

Appay V, Rowland-Jones S (2002) Premature ageing of the immune system: the cause of AIDS? Trends Immunol 23:580

Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, Little S, Havlir DV, Richman DD, Gruener N, Pape G, Waters A, easterbrook P, Salio M, Cerundolo V, McMichael AJ, Rowland-Jones SL (2002) Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8:379CrossRefPubMed

Azuma M, Phillips JH, Lanier LL (1993) CD28- T lymphocytes: antigenic and functional properties. J Immunol 150:1147PubMed

Ballen K, Stewart FM (1997) Adoptive immunotherapy. Curr Opin Oncol 9:579PubMed

Beverly B, Kang S, Lenardo M, Schwartz R (1992) Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol 4:661PubMed

Bodnar AG, Kim NW, Effros RB, Chiu CP (1996) Mechanism of telomerase induction during T cell activation. Exp Cell Res 228:58CrossRefPubMed

Boucher N, Defeu-Duchesne T, Vicaut E, Farge D, Effros RB, Schachter F (1998) CD28 expression in T cell aging and human longevity. Exp Gerontol 33:267CrossRefPubMed

Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, Casazza JP, Kuruppu J, Migueles SA, Connors M, Roederer M, Douek DC, Koup RA (2003) Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101:2711CrossRefPubMed

10.

Brenner MK, Heslop HE, Rooney CM (1998) Gene and cell transfer for specific immunotherapy. Vox Sang 74[Suppl 2]:87

11.

Brocker T, Karjalainen K (1998) Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors. Adv Immunol 68:257PubMed

12.

Campisi J (1997) The biology of replicative senescence. Eur J Cancer 33:703–709CrossRefPubMed

13.

Campisi J (2001) From cells to organisms: can we learn about aging from cells in culture? Exp Gerontol 36:607CrossRefPubMed

14.

Campisi J (2003) Cancer and ageing: rival demons? Nat Rev Cancer 3:339–349CrossRefPubMed

15.

Carlens S, Liu D, Ringden O, Aschan J, Christensson B, Levitsky V, Dilber MS (2002) Cytolytic T cell reactivity to Epstein-Barr virus is lost during in vitro T cell expansion. J Hematother Stem Cell Res 11:669CrossRefPubMed

16.

Chakraborty NG, Stevens RL, Mehrotra S, Laska E, Taxel P, Sporn JR, Schauer P, Albertsen PC (2003) Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother 52:497CrossRefPubMed

17.

Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay V, Rizzardi GP, Fleury S, Lipp M, Forster R, Rowland-Jones S, Sekaly RP, McMichael AJ, Pantaleo G (2001) Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410:106CrossRefPubMed

18.

Characiejus D, Pasukoniene V, Kazlauskaite N, Valuckas KP, Petraitis T, Mauricas M, Den Otter W (2002) Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma. Anticancer Res 22:3679PubMed

19.

Cheever MA, Chen W (1997) Therapy with cultured T cells: principles revisited. Immunol Rev 157:177PubMed

20.

Chiu CP, Harley CB (1997) Replicative senescence and cell immortality: the role of telomeres and telomerase. Proc Soc Exp Biol Med 214:99–106PubMed

21.

Chua D, Huang J, Zheng B, Lau SY, Luk W, Kwong DL, Sham JS, Moss D, Yuen KY, Im SW, Ng MH (2001) Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer 94:73CrossRefPubMed

22.

Cortesini R, LeMaoult J, Ciubotariu R, Cortesini NS (2001) CD8+CD28- T suppressor cells and the induction of antigen-specific antigen-presenting cells-mediated suppression of Th reactivity. Immunol Rev 182:201CrossRefPubMed

23.

Cristofalo V (1985) The destiny of cells: mechanisms and implications of senescence. Gerontologist 25:577PubMed

24.

Cutolo M, Sulli A, Seriolo B, Accardo S, Masi AT (1995) Estrogens, the immune response, and autoimmunity. Clin Exp Rheumatol 13:217PubMed

25.

Dagarag MD, Effros RB (2003) Ectopic telomerase expression prevents functional and phenotypic alterations associated with replicative senescence in virus-specific CD8 T cells. Clin Immunol (FOCIS Meeting Abstract Book)

26.

Dagarag MD, Ng H, Lubong R, Effros RB, Yang OO (2003) Differential impairment of lytic and cytokine functions in senescent HIV-1-specific cytotoxic T lymphocytes. J Virol 77:3077CrossRefPubMed

27.

Effros RB (1998) Replicative senescence in the immune system: impact of the Hayflick limit on T-cell function in the elderly. Am J Hum Genet 62:1003CrossRefPubMed

28.

Effros RB, Pawelec G (1997) Replicative senescence of T lymphocytes: does the Hayflick limit lead to immune exhaustion? Immunol Today 18:450–454CrossRefPubMed

29.

Effros RB, Boucher N, Porter V, Zhu X, Spaulding C, Walford RL, Kronenberg M, Cohen D, Schachter F (1994) Decline in CD28+ T cells in centenarians and in long-term T cell cultures: a possible cause for both in vivo and in vitro immunosenescence. Exp Gerontol 29:601CrossRefPubMed

30.

Effros RB, Zhu X, Walford RL (1994) Stress response of senescent T lymphocytes: reduced hsp70 is independent of the proliferative block. J Gerontol 49:B65PubMed

31.

Effros RB, Allsopp R, Chiu CP, Wang L, Hirji K, Harley CB, Villeponteau B, West M, Giorgi JV (1996) Shortened telomeres in the expanded CD28-CD8+ subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS/Fast Track 10:F17

32.

Effros RB, Cai Z, Linton PJ (2003) CD8 T cells and aging. Crit Rev Immunol 23:45PubMed

33.

Fernandez N, Duffour MT, Perricaudet M, Lotze MT, Tursz T, Zitvogel L (1998) Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines: principles and future prospects. Cytokines Cell Mol Ther 4:53PubMed

34.

Foss FM (2002) Immunologic mechanisms of antitumor activity. Semin Oncol 29:5CrossRef

35.

Fox HS, Bond BL, Parslow TG (1991) Estrogen regulates the IFN-gamma promoter. J Immunol 146:4362PubMed

36.

Freitas AA, Rocha B (2000) Population biology of lymphocytes: the flight for survival. Annu Rev Immunol 18:83CrossRefPubMed

37.

Gitlitz BJ, Belldegrun AS, Figlin RA (2001) Vaccine and gene therapy of renal cell carcinoma. Semin Urol Oncol 19:141PubMed

38.

Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O’Fallon WM, Weyand CM (2001) Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 75:12182CrossRefPubMed

39.

Grimm EA, Bruner JM, Carinhas J, Keoppen JA, Loudon WG, Owen-Schaub L, Steck PA, Moser RP (1990) Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype. Cancer Immunol Immunother 32:391

40.

Hakansson A, Hakansson L, Gustafsson B, Krysander L, Rettrup B, Ruiter D, Bernsen MR (2002) Biochemotherapy of metastatic malignant melanoma: on down-regulation of CD28. Cancer Immunol Immunother 51:499CrossRefPubMed

41.

Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR, Van Lier RA (1997) Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 186:1407CrossRefPubMed

42.

Hathcock KS, Weng NP, Merica R, Jenkins MK, Hodes R (1998) Antigen-dependent regulation of telomerase activity in murine T cells. J Immunol 160:5702PubMed

43.

Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek MA, Shay JW, Ishioka S, Yamakido M (1995) Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 155:3711PubMed

44.

Hooijberg E, Ruizendaal JJ, Snijders PJ, Kueter EW, Walboomers JM, Spits H (2000) Immortalization of human CD8+ T cell clones by ectopic expression of telomerase reverse transcriptase. J Immunol 165:4239PubMed

45.

Israel BF, Kenney SC (2003) Virally targeted therapies for EBV-associated malignancies. Oncogene 22:5122CrossRefPubMed

46.

Kennedy-Smith AG, McKenzie JL, Owen MC, Davidson PJ, Vuckovic S, Hart DN (2002) Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer. J Urol 168:741CrossRefPubMed

47.

Kitchingman GR, Rooney C (1998) Cytotoxic T cells and immunotherapy [comment]. Pediatr Radiol 28:489CrossRefPubMed

48.

Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J (2001) Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A 98:12072CrossRefPubMed

49.

Kyo S, Takakura M, Kanaya T, Zhuo W, Fujimoto K, Nishio Y, Orimo A, Inoue M (1999) Estrogen activates telomerase. Cancer Res 59:5917–5921PubMed

50.

Lanier LL (2001) A renaissance for the tumor immunosurveillance hypothesis. Nat Med 7:1178PubMed

51.

Looney RJ, Falsey A, Campbell D, Torres A, Kolassa J, Brower C, McCann R, Menegus M, McCormick K, Frampton M, Hall W, Abraham GN (1999) Role of cytomegalovirus in the T cell changes seen in elderly individuals. Clin Immunol 90:213CrossRefPubMed

52.

Maini MK, Soares MV, Zilch CF, Akbar AN, Beverley PC (1999) Virus-induced CD8+ T cell clonal expansion is associated with telomerase up-regulation and telomere length preservation: a mechanism for rescue from replicative senescence. J Immunol 162:4521PubMed

53.

Migliaccio M, Amacker M, Just T, Reichenbach P, Valmori D, Cerottini JC, Romero P, Nabholz M (2000) Ectopic human telomerase catalytic subunit expression maintains telomere length but is not sufficient for CD8+ T lymphocyte immortalization. J Immunol 165:4978PubMed

54.

Mitchell MS (2002) Cancer vaccines, a critical review--part I. Curr Opin Investig Drugs 3:140PubMed

55.

Mollet L, Sadat-Sowti B, Duntze J, Leblond V, Bergeron F, Calvez V, Katlama C, Debrae P, Autran B (1998) CD8hi+CD57+ T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity. Int Immunol 10:311CrossRefPubMed

56.

Monteiro J, Batliwalla F, Ostrer H, Gregersen PK (1996) Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J Immunol 156:3587PubMed

57.

Mori A, Takao S, Pradutkanchana J, Kietthubthew S, Mitarnun W, Ishida T (2003) High tumor necrosis factor-alpha levels in the patients with Epstein-Barr virus-associated peripheral T-cell proliferative disease/lymphoma. Leuk Res 27:493CrossRefPubMed

58.

O’Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L (1998) Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts. Springer Semin Immunopathol 20:455CrossRefPubMed

59.

Pardoll D (2001) T cells and tumours. Nature 411:1010–1012CrossRef

60.

Pawelec G (2003) Editorial statement from Graham Pawelec. Cancer Immunol Immunother 52

61.

Pawelec G, Schneider EM, Wernet P (1986) Acquisition of suppressive activity and natural killer-like cytotoxicity by human alloproliferative “helper” T cell clones. J Immunol 136:402PubMed

62.

Perillo NL, Naeim F, Walford RL, Effros RB (1993) The in vitro senescence of human lymphocytes: failure to divide is not associated with a loss of cytolytic activity or memory T cell phenotype. Mech Ageing Dev 67:173CrossRefPubMed

63.

Petersen JL, Morris CR, Solheim JC (2003) Virus evasion of MHC class I molecule presentation. J Immunol 171:4473PubMed

64.

Pittet MJ, Zippelius A, Speiser DE, Assenmacher M, Guillaume P, Valmori D, Lienard D, Lejeune F, Cerottini JC, Romero P (2001) Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol 166:7634PubMed

65.

Porter V (1994) Cellular senescence of T lymphocytes in vitro: a model system for the study of the age associated decline in immune functioning. Dissertation, UCLA Medical School

66.

Posnett DN, Sinha R, Kabak S, Russo C (1994) Clonal populations of T cells in normal elderly humans: the T cell equivalent to “benign monoclonal gammopathy”. J Exp Med 179:609PubMed

67.

Posnett DN, Edinger JW, Manavalan JS, Irwin C, Marodon G (1999) Differentiation of human CD8 T cells: implications for in vivo persistence of CD8⁺ CD28^- cytotoxic effector clones. Int Immunol 11:229CrossRefPubMed

68.

Salas AP, Chang AE (1998) Genetic approaches to adoptive cellular immunotherapy. Surg Oncol Clin N Am 7:487PubMed

69.

Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708CrossRefPubMed

70.

Saurwein-Teissl M, Lung TL, Marx F, Gschosser C, Asch E, Blasko I, Parson W, Bock G, Schonitzer D, Trannoy E, Grubeck-Loebenstein B (2002) Lack of antibody production following immunization in old age: association with CD8(+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 168:5893PubMed

71.

Schirmer M, Goldberger C, Wurzner R, Duftner C, Pfeiffer KP, Clausen J, Neumayr G, Falkenbach A (2002) Circulating cytotoxic CD8(+) CD28(-) T cells in ankylosing spondylitis. Arthritis Res 4:71CrossRefPubMed

72.

Schwab R, Szabo P, Manavalan JS, Weksler ME, Posnett DN, Pannetier C, Kourilsky P, Even J (1997) Expanded CD4+ and CD8+ T cell clones in elderly humans. J Immunol 158:4493PubMed

73.

Shay J, Wright W (1996) Telomerase activity in human cancer. Curr Opin Oncol 8:66PubMed

74.

Shimizu Y, Van Seventer G, Ennis E, Newman W, Horgan K, Shaw S (1992) Crosslinking of the T cell-specific accessory moleculesCD7 and CD28 modulates T cell adhesion. J Exp Med 175:577PubMed

75.

Smith JR and Pereira-Smith OM (1996) Replicative senescence: implications for in vivo aging and tumor suppression. Science 273:63PubMed

76.

Spaulding CS, Guo W, Effros RB (1999) Resistance to apoptosis in human CD8+ T cells that reach replicative senescence after multiple rounds of antigen-specific proliferation. Exp Gerontol 34:633CrossRefPubMed

77.

Straathof KC, Bollard CM, Rooney CM, Heslop HE (2003) Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist 8:83PubMed

78.

Sze DM, Giesajtis G, Brown RD, Raitakari M, Gibson J, Ho J, Baxter AG, Fazekas de St GB, Basten A, Joshua DE (2001) Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood 98:2817CrossRefPubMed

79.

Topp MS, Riddell SR, Akatsuka Y, Jensen MC, Blattman JN, Greenberg PD (2003) Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production. J Exp Med 198:947CrossRefPubMed

80.

Townsend SE, Allison JP (1993) Tumor rejection after direct costimulation of CD28+ T cells by B7-transfected melanoma cells. Science 259:368PubMed

81.

Tsai V, Kawashima I, Keogh E, Daly K, Sette A, Celis E (1998) In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells. Crit Rev Immunol 18:65PubMed

82.

Tsukishiro T, Donnenberg AD, Whiteside TL (2003) Rapid turnover of the CD8(+)CD28(-) T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother 52:599CrossRefPubMed

83.

Valenzuela HF, Effros RB (2002) Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus. Clin Immunol 105:117CrossRefPubMed

84.

Vaziri H, Schachter F, Uchida I, Wei L, Zhu X, Effros R, Cohen D, Harley C (1993) Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet 52:661

85.

Wang RF, Rosenberg SA (1996) Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. J Leukoc Biol 60:296PubMed

86.

Wang E, Lee MJ, Pandey S (1994) Control of fibroblast senescence and activation of programmed cell death. J Cell Biochem 54:432PubMed

87.

Weng NP, Levine BL, June CH, Hodes RJ (1995) Human naive and memory T lymphocytes differ in telomere length and replicative potential. Proc Natl Acad Sci U S A 92:11091PubMed

88.

Weng NP, Levine BL, June CH, Hodes RJ (1996) Regulated expression of telomerase activity in human T lymphocyte development and activation. J Exp Med 183:2471PubMed

89.

Wikby A, Johansson B, Olsson J, Lofgren S, Nilsson BO, Ferguson F (2002) Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol 37:445CrossRefPubMed

90.

Wills MR, Okecha G, Weekes MP, Gandhi MK, Sissons PJ, Carmichael AJ (2002) Identification of naive or antigen-experienced human CD8(+) T cells by expression of costimulation and chemokine receptors: analysis of the human cytomegalovirus-specific CD8(+) T cell response. J Immunol 168:5455PubMed

91.

Xu D, Erickson S, Szeps M, Gruber A, Sangfelt O, Einhorn S, Pisa P, Grander D (2000) Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood 96:4313PubMed

92.

Yee C, Riddell SR, Greenberg PD (1997) Prospects for adoptive T cell therapy. Curr Opin Immunol 9:702CrossRefPubMed

93.

Zanussi S, Vaccher E, Caffau C, Pratesi C, Crepaldi C, Bortolin MT, Tedeschi R, Politi D, Barzan L, Tirelli U, De Paoli P (2003) Interferon-gamma secretion and perforin expression are impaired in CD8+ T lymphocytes from patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 52:28PubMed

94.

Zhang D, Shankar P, Xu Z, Harnisch B, Chen G, Lange C, Lee SJ, Valdez H, Lederman MM, Lieberman J (2003) Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood 101:226CrossRefPubMed

Titel: Replicative senescence of CD8 T cells: potential effects on cancer immune surveillance and immunotherapy
verfasst von: Rita B. Effros
Publikationsdatum: 01.10.2004
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 10/2004
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-004-0508-x

Springer Medizin

Replicative senescence of CD8 T cells: potential effects on cancer immune surveillance and immunotherapy

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2004

The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape

Effective immunotherapy against cancer

Expression of NK-associated receptors on cytotoxic T cells from melanoma patients: a two-edged sword?

Down-regulation of ζ-chain expression in T cells: a biomarker of prognosis in cancer?

The paradox of T cell–mediated antitumor immunity in spite of poor clinical outcome in human melanoma

Tumour escape from the immune response

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie